Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 17, 2013, Pages

  Tharakaraman, Kannan ^a   Robinson, Luke N ^a   Hatas, Andrew ^a   Chen, Yi Ling ^a   Siyue, Liu ^b   Raguram, S ^a   Sasisekharan, V ^a   Wogan, Gerald N ^a   Sasisekharan, Ram ^a,b  

^a Koch Institute of Integrative Cancer Research   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Affinity enhancement; Antibody engineering; Computational docking; Infectious diseases; Therapeutic

Indexed keywords

CROSS REACTING ANTIBODY;

ARTICLE; CRYSTAL STRUCTURE; DENGUE VIRUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SEROTYPE; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; BINDING SITES, ANTIBODY; CROSS REACTIONS; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; MICE; MODELS, IMMUNOLOGICAL; PROTEIN BINDING; PROTEIN ENGINEERING; REAL-TIME POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE;

DENGUE VIRUS;

EID: 84876862822     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303645110     Document Type: Article

References (51)

1. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5): 343-357.
2. Griffiths AD, Duncan AR (1998) Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 9(1):102-108.
3. Hoogenboom HR (1997) Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol 15(2):62-70.
4. Clark LA, et al. (2006) Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci 15(5):949-960.
5. Marvin JS, Lowman HB (2003) Redesigning an antibody fragment for faster association with its antigen. Biochemistry 42(23):7077-7083.
6. Lippow SM, Wittrup KD, Tidor B (2007) Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 25(10):1171-1176.
7. Guzman MG, et al. (2010) Dengue: A continuing global threat. Nat Rev Microbiol 8(12, Suppl):S7-S16.
8. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62:71-92.
9. Gubler DJ (2011) Dengue, urbanization and globalization: The unholy trinity of the 21st Century. Trop Med Health 39(4, Suppl):3-11.
10. McBride WJ, Bielefeldt-Ohmann H (2000) Dengue viral infections: Pathogenesis and epidemiology. Microbes Infect 2(9):1041-1050.
11. Whitehead SS, Blaney JE, Durbin AP, Murphy BR (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5(7):518-528.
12. Thomas SJ, Endy TP (2011) Critical issues in dengue vaccine development. Curr Opin Infect Dis 24(5):442-450.
13. Sabchareon A, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380(9853):1559-1567.
14. Wahala WM, Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3(12):2374-2395.
15. Lai CY, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82(13):6631-6643.
16. Lok SM, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15(3):312-317.
17. Thullier P, et al. (1999) A recombinant Fab neutralizes dengue virus in vitro. J Biotechnol 69(2-3):183-190.
18. Thullier P, et al. (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82(Pt 8):1885-1892.
19. Pedotti M, Simonelli L, Livoti E, Varani L (2011) Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin. Int J Mol Sci 12(1):226-251.
20. Mohan V, Gibbs AC, Cummings MD, Jaeger EP, DesJarlais RL (2005) Docking: Successes and challenges. Curr Pharm Des 11(3):323-333.
21. Simonelli L, et al. (2010) Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking. J Mol Biol 396(5):1491-1507.
22. Chen R, Li L, Weng Z (2003) ZDOCK: An initial-stage protein-docking algorithm. Proteins 52(1):80-87.
23. Pierce B, Weng Z (2007) ZRANK: Reranking protein docking predictions with an optimized energy function. Proteins 67(4):1078-1086.
24. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 101(34):12467-12472.
25. Fellouse FA, et al. (2005) Molecular recognition by a binary code. J Mol Biol 348(5): 1153-1162.
26. Farady CJ, Sellers BD, Jacobson MP, Craik CS (2009) Improving the species cross-reactivity of an antibody using computational design. Bioorg Med Chem Lett 19(14):3744-3747.
27. Lisova O, Hardy F, Petit V, Bedouelle H (2007) Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol 88(Pt 9):2387-2397.
28. Bedouelle H, et al. (2006) Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J 273(1):34-46.
29. Darnell SJ, Page D, Mitchell JC (2007) An automated decision-tree approach to predicting protein interaction hot spots. Proteins 68(4):813-823.
30. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77(2):305-319.
31. Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine testing. J Virol 73(1):783-786.
32. Cockburn JJ, et al. (2012) Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20(2):303-314.
33. Corti D, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):850-856.
34. Kuroda D, Shirai H, Jacobson MP, Nakamura H (2012) Computer-aided antibody design. Protein Eng Des Sel 25(10):507-521.
35. Fleishman SJ, et al. (2011) Community-wide assessment of protein-interface modeling suggests improvements to design methodology. J Mol Biol 414(2):289-302.
36. Hwang H, Vreven T, Pierce BG, Hung JH, Weng Z (2010) Performance of ZDOCK and ZRANK in CAPRI rounds 13-19. Proteins 78(15):3104-3110.
37. Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc Natl Acad Sci USA 93(1):13-20.
38. Barderas R, Desmet J, Timmerman P, Meloen R, Casal JI (2008) Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci USA 105(26):9029-9034.
39. Selzer T, Albeck S, Schreiber G (2000) Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol 7(7):537-541.
40. Schreiber G, Fersht AR (1996) Rapid, electrostatically assisted association of proteins. Nat Struct Biol 3(5):427-431.
41. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587-619.
42. Laoprasopwattana K, et al. (2005) Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192(3):510-519.
43. Endy TP, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189(6):990-1000.
44. Beltramello M, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3):271-283.
45. Ramaraj T, Angel T, Dratz EA, Jesaitis AJ, Mumey B (2012) Antigen-antibody interface properties: Composition, residue interactions, and features of 53 non-redundant structures. Biochim Biophys Acta 1824(3):520-532.
46. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215(3):403-410.
47. Comeau SR, Gatchell DW, Vajda S, Camacho CJ (2004) ClusPro: An automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20(1):45-50.
48. Lorenzen S, Zhang Y (2007) Identification of near-native structures by clustering protein docking conformations. Proteins 68(1):187-194.
49. Martineau P (2010) Affinity measurements by competition ELISA. Antibody Engineering, eds Kontermann R, Dubel S (Springer, Berlin), Vol 1, pp 657-665.
50. Bobrovnik SA (2003) Determination of antibody affinity by ELISA. Theory. J Biochem Biophys Methods 57(3):213-236.
51. van den Broek MF, Müller U, Huang S, Aguet M, Zinkernagel RM (1995) Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol 69(8):4792-4796.